Clinical validation analyses were performed in two independent lung cancer patient cohorts to identify positive nuclear co-expression of the MEOX2 and GLI-1 proteins in situ in solid lung carcinomas derived from 20 lung cancer patients in the “INER cohort” or 90 lung cancer patients in the “INCAN cohort” in the context of clinical outcomes (Table II), supporting our hypothesis regarding the existence of a novel co-regulatory axis involving association of the MEOX2 protein with GLI-1 gene promoter sequences in human NSCLC. The gene discussed is MEOX2; the disease is lung carcinoma.